Vivos Therapeutics signs $9M deal to acquire Nevada sleep center operator SCN

Vivos Therapeutics, Inc.

Total consideration up to $9M: $6M cash + $1.5M stock at closing + $1.5M stock earn-out.
SCN sees ~3,000 new patients/month; annual revenue in high seven figures; 7 locations in Nevada.
Close expected Q2/Q3 2025, subject to financing, audit, and customary conditions; no shareholder vote needed.
Employment agreement for Dr. Rachakonda includes $400K salary and board observation right; New Seneca Partners assisted.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.